

# Integrated Filing (Finance) Ind AS

## ORCHID PHARMA LIMITED

### General Information

Scrip code*	524372
NSE Symbol*	ORCHPHARMA
MSEI Symbol*	NOTLISTED
ISIN*	INE191A01027
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2024
Date of end of financial year	31-03-2025
Date of board meeting when results were approved	26-05-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	20-05-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Pharmaceuticals
Start date of board meeting	26-05-2025
Start time of board meeting	12:00:00
End date of board meeting	26-05-2025
End time of board meeting	15:35:00
Whether cash flow statement is applicable on company	true
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Statement on impact of audit qualification

## Financial Results - Ind-AS

Amount in (Lakhs)

Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-01-2025	01-04-2024
Date of end of reporting period	31-03-2025	31-03-2025
Whether results are audited or unaudited	Audited	Audited
Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>	
1	<b>Income</b>	
	Revenue from operations	23,747.87
	Other income	389.72
	<b>Total income</b>	<b>24,137.59</b>
2	<b>Expenses</b>	
(a)	Cost of materials consumed	13,694.46
(b)	Purchases of stock-in-trade	124.40
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(17.24)
(d)	Employee benefit expense	2,224.24
(e)	Finance costs	391.50
(f)	Depreciation, depletion and amortisation expense	887.17
(g)	<b>Other Expenses</b>	
1	Other Expenses	4,923.65
	<b>Total other expenses</b>	<b>4,923.65</b>
	<b>Total expenses</b>	<b>22,228.18</b>
3	<b>Total profit before exceptional items and tax</b>	
	1,909.41	9,556.48
4	Exceptional items	
	0.00	0.00
5	<b>Total profit before tax</b>	
	1,909.41	9,556.48
6	<b>Tax expense</b>	
7	Current tax	
	0.00	0.00
8	Deferred tax	
	(3.94)	(19.35)
9	<b>Total tax expenses</b>	
	(3.94)	(19.35)
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	
	0.00	0.00
11	<b>Net Profit Loss for the period from continuing operations</b>	
	1,913.35	9,575.83
12	Profit (loss) from discontinued operations before tax	
	0.00	0.00
13	Tax expense of discontinued operations	
	0.00	0.00
14	<b>Net profit (loss) from discontinued operation after tax</b>	
	0.00	0.00
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	
	316.11	389.85
16	<b>Total profit (loss) for period</b>	
	2,229.46	9,965.68
17	Other comprehensive income net of taxes	
	166.75	(75.13)
18	<b>Total Comprehensive Income for the period</b>	
	2,396.21	9,890.55
19	<b>Total profit or loss, attributable to</b>	

	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21	<b>Details of equity share capital</b>		
	Paid-up equity share capital	5,071.91	5,071.91
	Face value of equity share capital	10.00	10.00
22	Reserves excluding revaluation reserve		0.00
23	<b>Earnings per share</b>		
i	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	4.40	19.65
	Diluted earnings (loss) per share from continuing operations	4.40	19.65
ii	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0.00	0.00
	Diluted earnings (loss) per share from discontinued operations	0.00	0.00
iii	<b>Earnings per equity share (for continuing and discontinued operations)</b>		
	Basic earnings (loss) per share from continuing and discontinued operations	4.40	19.65
	Diluted earnings (loss) per share from continuing and discontinued operations	4.40	19.65
24	Debt equity ratio		
25	Debt service coverage ratio		
26	Interest service coverage ratio		
27	Remarks for debt equity ratio		
28	Remarks for debt service coverage ratio		
29	Remarks for interest service coverage ratio		
30	Disclosure of notes on financial results	Textual Information(1)	

## Text Block

Textual Information(1)	<p>1. The above results for the quarter and year ended March 31 , 2025 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on May 26, 2025. The statutory auditors of the company have expressed an unmodified opinion on the audited Standalone results and a modified opinion on the audit of the Consolidated results. 2.The Statement has been prepared in accordance with the recognition and measurement principles 01 the Companies Indian Accounting Standards rind AS') as prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended from tim; to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. 3. 99,02.705 fully paid up Equity Shares of face value ~ 1 Of- each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement (aIP) whereby proceeds of Rs.39180 Lakhs (Net of Share issue expenses) was raised. As on September 30, 2024 the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below : Statement of QIP Net Funds raised and utilisation Particulars Amount as stated in Total amount utilised *Balance amount as on Remarks the Offer Document upto March 31, 2025 on September 30, 2024 kept (Rs. In Lakhs) (Rs. In Lakhs) in Fixed Deposits (in lakhs) 1)Investment in OBPL (subsidiary) for setting up Jammu Manufacturing Facility 9000 4416 4584 2)Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the company 14100 14100 - 3)Funding capital expenditure requirements for setting up a new block at the API facility of the Company in Alathur, Tamil Nadu 9982 36 9946 4)General corporate purposes 6098 6372 0 # Total 39180 42924 14530 #As per the QIP offer Document the amount allocated for General Corporate Purpose (GCP) was Rs. 6098 Lakh which was based on then proposed net proceeds after issue expenses being Rs.39180 Lakh. However, net proceeds transferred to Monitoring Account was Rs. 39454 Lakh as against the proposed net Proceeds of Rs. 39180 Lakh, therefore the Surplus amount of Rs. 274 Lakh has been included in the GCP balance as on March 31, 2025. * Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits. 4. The operations of the Company falls under a single operating segment i.e., "Pharmaceuticals" in accordance with Ind AS 108 "Operating Segments" and hence no reporting as per Ind AS 108 is applicable. 5. The figures for the quarters ended 31st March, 2025 and 31st March, 2024 are the balancing figures between audited figures in respect of the full financial year and year to date figures up to the third quarter of the relevant financial years which were subjected to limited review. 6. The Company has submitted a petition with the Hon'ble National Company Law Tribunal, Chennai</p>
------------------------	--

bench, for amalgamation of its Holding Company Dhanuka Laboratories Limited ("the Amalgamating Company") with the Company in compliance with Section 230-232 and other relevant provisions of the Companies Act 2013 . The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, in compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation Letter from the BSE Limited and National Stock Exchange of India Limited ("stock exchanges") giving No objection to the said amalgamation. Further, the Hon'ble NCI T have pronounced the order dated 29th April, 2025 , inter-alia, issuing directions for convening meetings of equity shareholders of the Company and unsecured creditors of both Companies and dispensed off the meetings of equity shareholders of the Amalgamating Company and secured creditors of both the Companies, considering their respective consents to the Scheme already submitted before the Hon'ble NCI T. The management of the respective Companies are taking steps to comply with the said Order. 7. Figures of the previous period have been regrouped/reclassified /restated wherever considered necessary.

## Other Comprehensive Income

Amount in (Lakhs)

Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-01-2025	01-04-2024
Date of end of reporting period	31-03-2025	31-03-2025
Whether results are audited or unaudited	Audited	Audited
Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Other comprehensive income [Abstract]</b>		
<b>1 Amount of items that will not be reclassified to profit and loss</b>		
1 Items that will not be classified to profit or loss	166.75	(75.13)
Total Amount of items that will not be reclassified to profit and loss	166.75	(75.13)
2 Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00
<b>3 Amount of items that will be reclassified to profit and loss</b>		
Total Amount of items that will be reclassified to profit and loss		
4 Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5 Total Other comprehensive income		

## Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars	Year ended (dd-mm- yyyy)
Date of start of reporting period	01-04-2024
Date of end of reporting period	31-03-2025
Whether results are audited or unaudited	Audited
Nature of report standalone or consolidated	Consolidated
<b>Assets</b>	
<b>1 Non-current assets</b>	
Property, plant and equipment	63,158.54
Capital work-in-progress	6,448.93
Investment property	0.00
Goodwill	112.53
Other intangible assets	0.00
Intangible assets under development	1,622.36
Biological assets other than bearer plants	0.00
Investments accounted for using equity method	0.00
<b>Non-current financial assets</b>	
Non-current investments	4,967.06
Trade receivables, non-current	0.00
Loans, non-current	0.00
Other non-current financial assets	426.98
<b>Total non-current financial assets</b>	5,394.04
Deferred tax assets (net)	5,130.15
Other non-current assets	6,183.19
<b>Total non-current assets</b>	88,049.74
<b>2 Current assets</b>	
Inventories	32,637.15
<b>Current financial asset</b>	
Current investments	0.00
Trade receivables, current	24,183.21
Cash and cash equivalents	2,110.68
Bank balance other than cash and cash equivalents	15,852.57
Loans, current	0.00
Other current financial assets	304.36
<b>Total current financial assets</b>	42,450.82
Current tax assets (net)	277.41
Other current assets	5,376.35
<b>Total current assets</b>	80,741.73
3 Non-current assets classified as held for sale	0.00
4 Regulatory deferral account debit balances and related deferred tax Assets	0.00
<b>Total assets</b>	1,68,791.47
<b>Equity and liabilities</b>	
<b>1 Equity</b>	
<b>Equity attributable to owners of parent</b>	
Equity share capital	5,071.91
Other equity	1,21,656.63
<b>Total equity attributable to owners of parent</b>	1,26,728.54
Non controlling interest	0.00
<b>Total equity</b>	1,26,728.54

<b>2</b>	<b>Liabilities</b>	
	<b>Non-current liabilities</b>	
	<b>Non-current financial liabilities</b>	
	Borrowings, non-current	13,163.58
	<b>Trade payables, non-current</b>	
	(A) Total outstanding dues of micro enterprises and small enterprises	0.00
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0.00
	<b>Total Trade payable</b>	0.00
	Other non-current financial liabilities	0.00
	<b>Total non-current financial liabilities</b>	13,163.58
	Provisions, non-current	338.72
	Deferred tax liabilities (net)	0.00
	Deferred government grants, Non-current	0.00
	Other non-current liabilities	3.67
	<b>Total non-current liabilities</b>	13,505.97
	<b>Current liabilities</b>	
	<b>Current financial liabilities</b>	
	Borrowings, current	4,260.33
	<b>Trade payables, current</b>	
	(A) Total outstanding dues of micro enterprises and small enterprises	1,102.34
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	21,106.87
	<b>Total Trade payable</b>	22,209.21
	Other current financial liabilities	0.00
	<b>Total current financial liabilities</b>	26,469.54
	Other current liabilities	1,850.82
	Provisions, current	236.60
	Current tax liabilities (Net)	0.00
	Deferred government grants, Current	0.00
	<b>Total current liabilities</b>	28,556.96
3	Liabilities directly associated with assets in disposal group classified as held for sale	0.00
4	Regulatory deferral account credit balances and related deferred tax liability	0.00
	<b>Total liabilities</b>	42,062.93
	<b>Total equity and liabilities</b>	1,68,791.47
	Disclosure of notes on assets and liabilities	

## Cash flow statement indirect

Amount in (Lakhs)

Particulars	Year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2024
Date of end of reporting period	31-03-2025
Whether results are audited or unaudited	Audited
Nature of report standalone or consolidated	Consolidated
<b>Part I</b>	
<b>Blue color marked fields are non-mandatory.</b>	
<b>1 Statement of cash flows</b>	
<b>Cash flows from used in operating activities</b>	
Profit before tax	9,556.48
<b>2 Adjustments for reconcile profit (loss)</b>	
Adjustments for finance costs	1,454.01
Adjustments for decrease (increase) in inventories	(6,214.54)
Adjustments for decrease (increase) in trade receivables, current	(4,906.60)
Adjustments for decrease (increase) in trade receivables, non-current	684.11
Adjustments for decrease (increase) in other current assets	452.19
Adjustments for decrease (increase) in other non-current assets	31.98
Adjustments for other financial assets, non-current	169.39
Adjustments for other financial assets, current	0.00
Adjustments for other bank balances	0.00
Adjustments for increase (decrease) in trade payables, current	0.00
Adjustments for increase (decrease) in trade payables, non-current	(678.23)
Adjustments for increase (decrease) in other current liabilities	0.00
Adjustments for increase (decrease) in other non-current liabilities	0.00
Adjustments for depreciation and amortisation expense	3,454.58
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0.00
Adjustments for provisions, current	0.00
Adjustments for provisions, non-current	324.50
Adjustments for other financial liabilities, current	0.00
Adjustments for other financial liabilities, non-current	0.00
Adjustments for unrealised foreign exchange losses gains	(584.88)
Adjustments for dividend income	0.00
Adjustments for interest income	0.00
Adjustments for share-based payments	0.00
Adjustments for fair value losses (gains)	0.00
Adjustments for undistributed profits of associates	0.00
Other adjustments for which cash effects are investing or financing cash flow	0.00
Other adjustments to reconcile profit (loss)	0.00
Other adjustments for non-cash items	0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0.00
<b>Total adjustments for reconcile profit (loss)</b>	<b>(5,813.49)</b>

	<b>Net cash flows from (used in) operations</b>	3,742.99
	Dividends received	0.00
	Interest paid	1,727.74
	Interest received	0.00
	Income taxes paid (refund)	93.74
	Other inflows (outflows) of cash	0.00
	<b>Net cash flows from (used in) operating activities</b>	1,921.51
<b>3</b>	<b>Cash flows from used in investing activities</b>	
	Cash flows from losing control of subsidiaries or other businesses	0.00
	Cash flows used in obtaining control of subsidiaries or other businesses	0.00
	Other cash receipts from sales of equity or debt instruments of other entities	0.00
	Other cash payments to acquire equity or debt instruments of other entities	0.00
	Other cash receipts from sales of interests in joint ventures	0.00
	Other cash payments to acquire interests in joint ventures	0.00
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0.00
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0.00
	Proceeds from sales of property, plant and equipment	0.00
	Purchase of property, plant and equipment	15,010.80
	Proceeds from sales of investment property	0.00
	Purchase of investment property	0.00
	Proceeds from sales of intangible assets	0.00
	Purchase of intangible assets	0.00
	Proceeds from sales of intangible assets under development	0.00
	Purchase of intangible assets under development	0.00
	Proceeds from sales of goodwill	0.00
	Purchase of goodwill	0.00
	Proceeds from biological assets other than bearer plants	0.00
	Purchase of biological assets other than bearer plants	0.00
	Proceeds from government grants	0.00
	Proceeds from sales of other long-term assets	0.00
	Purchase of other long-term assets	0.00
	Cash advances and loans made to other parties	0.00
	Cash receipts from repayment of advances and loans made to other parties	0.00
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0.00
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	10,443.85
	Dividends received	0.00
	Interest received	1,873.86
	Income taxes paid (refund)	0.00
	Other inflows (outflows) of cash	0.00
	<b>Net cash flows from (used in) investing activities</b>	(2,693.09)
<b>4</b>	<b>Cash flows from used in financing activities</b>	
	Proceeds from changes in ownership interests in subsidiaries	0.00
	Payments from changes in ownership interests in subsidiaries	0.00
	Proceeds from issuing shares	0.00
	Proceeds from issuing other equity instruments	0.00

	Payments to acquire or redeem entity's shares	0.00
	Payments of other equity instruments	0.00
	Proceeds from exercise of stock options	0.00
	Proceeds from issuing debentures notes bonds etc	0.00
	Proceeds from borrowings	2,855.58
	Repayments of borrowings	22.07
	Payments of lease liabilities	0.00
	Dividends paid	0.00
	Interest paid	311.34
	Income taxes paid (refund)	0.00
	Other inflows (outflows) of cash	0.00
	<b>Net cash flows from (used in) financing activities</b>	<b>2,522.17</b>
	<b>Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</b>	<b>1,750.59</b>
<b>5</b>	<b>Effect of exchange rate changes on cash and cash equivalents</b>	
	Effect of exchange rate changes on cash and cash equivalents	0.00
	<b>Net increase (decrease) in cash and cash equivalents</b>	<b>1,750.59</b>
	<b>Cash and cash equivalents cash flow statement at beginning of period</b>	<b>360.09</b>
	<b>Cash and cash equivalents cash flow statement at end of period</b>	<b>2,110.68</b>

## Details of Impact of Audit Qualification

Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Statement on impact of audit qualification	
Auditor's opinion		Qualified opinion	
Declaration pursuant to Regulation 33(3)(d) of SEBI(LODR) Regulation, 2015:The company declares that its Statutory Auditor / s have issued an Audit Report with unmodified opinion for the period on Consolidated results			
Sr.No	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Singhi & Co.	true	31-08-2025

## Financial details

Amount in (Lakhs)

Sr.	Particulars	Audited Figures (as reported before adjusting for qualifications)	Adjusted Figures (audited figures after adjusting for qualifications)
1	Turnover / Total income	95,329.91	95,329.91
2	Total Expenditure	85,364.23	85,364.23
3	Net Profit/(Loss)	9,965.68	9,965.68
4	Earnings Per Share	19.65	19.65
5	Total Assets	1,68,791.47	1,68,791.47
6	Total Liabilities	42,062.93	42,062.93
7	Net Worth	1,26,728.54	1,26,728.54

## Audit qualification

Sr.	Details of Audit Qualification	Type of Audit Qualification	Frequency of qualification	For Audit Qualification(s) where the impact is quantified by the auditor	For Audit Qualification(s) where the impact is not quantified by the auditor		
				Management's Views	(i) Management's estimation on the impact of audit qualification	(ii) If management is unable to estimate the impact, reasons for the same	Auditor's Comment on (i) or (ii)
1	Textual Information(1)	Qualified opinion	Repetitive	Textual Information(2)	Textual Information(3)	Textual Information(4)	Textual Information(5)

## Text Block

Textual Information(1)	<p>The Consolidated Financial Statements for the year ended March 31, 2025 include the financial statements for the year ended March 31, 2025, of the following subsidiary compames: (i) Orchid Pharmaceuticals Inc., USA (ii) Bexel Pharmaceuticals Inc., USA (iii)Orchid Pharmaceuticals SA (Proprietary) Limited, South Africa (Upto 31 sl January 2024) (iv) Diakron Pharmaceuticals, Inc. USA We did not audit the financial statements of the above subsidiaries whose financial statements reflect total Assets of RS.349.09 Lakhs as at March 31, 2025, total revenue from operations of Rs. Nil, total comprehensive income after tax of Rs.(-) 634.35 Lakhs for the year ended March 31,2025 and net cash flows amounting to Rs. Nil for the year ended on that date as considered in the consolidated financial statements. The financial statements of the above subsidiaries are unaudited and have been furnished to us by the management and our opinion on the Consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of the subsidiaries and associate, is based solely on such unaudited financial statements. Accordingly, we do not express any opinion on the completeness and true and fair view of the financial statements, including adjustments, if any, required on the carrying amount of assets and liabilities of the above subsidiaries and associate and foreign currency translation reserve as at March 31,2025 included in the consolidated financial statements. This has also been qualified in the Limited Review reports of the earlier quarters and audit reports of the earlier years, audited by the predecessor auditor.</p>
Textual Information(2)	Not Applicable
Textual Information(3)	Not Applicable
Textual Information(4)	<p>The subsidiaries of the Company are located in USA and South Africa. Audit is not compulsory for companies in USA, if they are not publicly traded Orchid Pharmaceuticals SA (Proprietary) Limited, South Africa have been closed ill January 2024. Orchid Pharmaceauticals Inc is now audited upto March 31, 2023. Further transactions ill majority of the above subsidiaries are either Nil or very minimum. Hence the management has used unaudited financials for the purpose of consolidation.</p>
Textual Information(5)	Refer "Basis for Qualified Opinion" in our audit report.

## Signatories details

Name of CEO / Managing director	Manish Dhanuka
Name of CFO	Sunil Kumar Gupta
Name of audit committee chairman	Manoj Goyal
Name of statutory auditor	Singhi & Co.
Name of other signatory, if any, with designation	
Place	Gurugram
Date	26-05-2025